12-Week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously in Subjects With Type 1 or 2 Diabetes Mellitus Also Using Lantus (Insulin Glargine).
Latest Information Update: 24 Apr 2013
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 17 Jul 2008 Actual patient number added (485) as reported by ClinicalTrials.gov.
- 17 Jul 2008 Actual end date added (Jun 2008) as reported by ClinicalTrials.gov.
- 17 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.